Nuformix further evaluating NXP002 combination therapies now underway

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis.

As previously announced, the Company has initiated studies in 3D human IPF lung tissue using a disease and species relevant model, and is working with its partner, Fibrofind, focusing on NXP002 in combination with current standards of care.  Suitable human disease tissue, which is highly limited in supply, has now been acquired allowing the practical elements of the study to commence, with results and further updates to be announced in due course.

NXP002 combinations have already shown promise in human diseased IPF tissue, showing a pleasing synergistic efficacy effect with low doses of standards-of-care, resulting in the Group filing a new combination patent application in 2022.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: We’ve had to wait a little longer than expected to acquire suitable tissue, but I’m delighted that the main element of this key study, further evaluating NXP002 combination therapies is now underway and I look forward to sharing the results when they are available.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix updates on the NXP002 programme for treatment of IPF

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled

Nuformix plc

Nuformix updates on NXP004

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP004 programme, focused on the development of novel, proprietary, cocrystal forms of olaparib,

Nuformix plc

Nuformix excited by prospects for the remainder of the year

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 30 September 2022. Operational highlights (including post-period end) ·      Initial pre-clinical inhalation studies undertaken

Nuformix plc

Nuformix to host online presentation and Q&A session

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Wednesday 9

Nuformix plc

Nuformix lead programme introduced to major respiratory players (VIDEO)

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment

Nuformix plc

Nuformix introduces lead programme to major respiratory players

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment

Nuformix plc

Campaign calls for diagnosis of pulmonary fibrosis

The president of the Portuguese Society of Pulmonology, António Morais, warned that patients should not underestimate symptoms and insisted on the importance of early diagnosis in fibrotic diseases, stressing that it is crucial to stop progression. The campaign

Nuformix plc

Almost half of cancer deaths are preventable

Nearly 50% of cancer deaths worldwide are caused by preventable risk factors, such as smoking and drinking alcohol, according to the largest study of the link between cancer burden and risk factors1. Using estimates of cancer cases and

Nuformix plc

PF awareness means ‘Being here for each other’ in September

From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds

Nuformix plc

What is cancer?

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body.  Cancer can start almost anywhere in the human body, which is made up of trillions of cells.

Nuformix plc

Cancer warning signs

Cancer is the leading cause of death globally, the World Health Organisation says, killing almost 10 million people each year. While about one in six deaths are due to cancer, many forms of the disease can be cured if they

Nuformix plc

COVID-19 and IPF: Fundamental similarities found

An AI-guided analysis of more than 1000 human lung transcriptomic datasets found that COVID-19 resembles idiopathic pulmonary fibrosis (IPF) at a fundamental level, according to a study published July 20, 2022. In the aftermath of COVID-19, a significant number of

Nuformix plc

Nuformix progressing to robustly investigate NXP002’s efficacy

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that NXP002, a new form of tranilast and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis, has successfully

Nuformix plc

Nuformix to continue to optimise value from its existing assets

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the year ended 31 March 2022. Non-executive Directors’ Statement Introduction Following the departure of

Nuformix plc

Can you have both pulmonary fibrosis and emphysema together?

Combined pulmonary fibrosis and emphysema (CPFE) is a condition that causes symptoms of both pulmonary fibrosis and emphysema. People with CPFE have both air sac destruction (seen in people with emphysema) and also scarred lung tissue of what

Nuformix plc

Virtual, in-person events planned for 2022 PFF Walk

The Pulmonary Fibrosis Foundation (PFF) is hosting its sixth annual PFF Walk fundraiser with virtual and in-person events over the next few months to raise funds and awareness in support of people living with pulmonary fibrosis. “We encourage everyone to join

No more posts to show